Thereby BETi’s sensitizes cancer cells, even in RB1-deficient cells, to CDK4/6 inhibitors, which have currently been approved for the treatment of hormone-positive breast cancers [136,137,138,139]. The gene discussed is CDK4; the disease is cancer.